Clem BF - Search Results

1

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.

Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, Milam RA, Rai SN, Pan J, Gragg H, Clem BF, McMasters KM, Miller DM, Chesney J. Telang S, et al. Among authors: clem bf, clem al. BMC Cancer. 2011 Dec 13;11:515. doi: 10.1186/1471-2407-11-515. BMC Cancer. 2011. PMID: 22165955 Free PMC article. Clinical Trial.

2

Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.

Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, Lane A, Trent JO, Chesney J. Clem B, et al. Mol Cancer Ther. 2008 Jan;7(1):110-20. doi: 10.1158/1535-7163.MCT-07-0482. Mol Cancer Ther. 2008. PMID: 18202014

3

The Rb/E2F pathway and Ras activation regulate RecQ helicase gene expression.

Liu Y, El-Naggar S, Clem B, Chesney J, Dean DC. Liu Y, et al. Biochem J. 2008 Jun 1;412(2):299-306. doi: 10.1042/BJ20070975. Biochem J. 2008. PMID: 18215118

4

Targeting aspartate aminotransferase in breast cancer.

Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, Eaton JW, Telang S, Chesney J. Thornburg JM, et al. Among authors: clem bf. Breast Cancer Res. 2008;10(5):R84. doi: 10.1186/bcr2154. Epub 2008 Oct 15. Breast Cancer Res. 2008. PMID: 18922152 Free PMC article.

5

Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype.

Liu Y, Clem B, Zuba-Surma EK, El-Naggar S, Telang S, Jenson AB, Wang Y, Shao H, Ratajczak MZ, Chesney J, Dean DC. Liu Y, et al. Cell Stem Cell. 2009 Apr 3;4(4):336-47. doi: 10.1016/j.stem.2009.02.015. Cell Stem Cell. 2009. PMID: 19341623 Free PMC article.

6

Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer.

Yalcin A, Telang S, Clem B, Chesney J. Yalcin A, et al. Exp Mol Pathol. 2009 Jun;86(3):174-9. doi: 10.1016/j.yexmp.2009.01.003. Epub 2009 Jan 14. Exp Mol Pathol. 2009. PMID: 19454274 Review.

7

Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases.

Yalcin A, Clem BF, Simmons A, Lane A, Nelson K, Clem AL, Brock E, Siow D, Wattenberg B, Telang S, Chesney J. Yalcin A, et al. Among authors: clem bf, clem al. J Biol Chem. 2009 Sep 4;284(36):24223-32. doi: 10.1074/jbc.M109.016816. Epub 2009 May 27. J Biol Chem. 2009. PMID: 19473963 Free PMC article.

8

Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling.

Yalcin A, Clem B, Makoni S, Clem A, Nelson K, Thornburg J, Siow D, Lane AN, Brock SE, Goswami U, Eaton JW, Telang S, Chesney J. Yalcin A, et al. Oncogene. 2010 Jan 7;29(1):139-49. doi: 10.1038/onc.2009.317. Epub 2009 Oct 26. Oncogene. 2010. PMID: 19855431

9

A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling.

Clem BF, Clem AL, Yalcin A, Goswami U, Arumugam S, Telang S, Trent JO, Chesney J. Clem BF, et al. Among authors: clem al. Oncogene. 2011 Jul 28;30(30):3370-80. doi: 10.1038/onc.2011.51. Epub 2011 Mar 21. Oncogene. 2011. PMID: 21423211 Free PMC article.

10

Block copolymer micelles for controlled delivery of glycolytic enzyme inhibitors.

Akter S, Clem BF, Lee HJ, Chesney J, Bae Y. Akter S, et al. Among authors: clem bf. Pharm Res. 2012 Mar;29(3):847-55. doi: 10.1007/s11095-011-0613-4. Epub 2011 Oct 28. Pharm Res. 2012. PMID: 22033882

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters